SCHEMBL17744147

SCHEMBL17744147

C=COCCOCCCCCCCCC=CCC=CCCCCC

nearest known ligand 0.69

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.46
CNR1 P21554 1/20 0.46
CNR2 P34972 1/20 0.46
TRPV1 Q8NER1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17744145 1.00 ALDH1A1 (0.46) ALDH1A1CNR1CNR2TRPV1
SCHEMBL29174557 0.90 ALDH1A1 (0.51) ALDH1A1CNR1CNR2TRPV1
SCHEMBL3452404 0.90 ALDH1A1 (0.51) ALDH1A1CNR1CNR2TRPV1
SCHEMBL29174551 0.88 ALDH1A1 (0.53) ALDH1A1CNR1CNR2TRPV1
SCHEMBL237980 0.88 ALDH1A1 (0.56) ALDH1A1CNR1CNR2TRPV1
SCHEMBL13609157 0.86 HTT (0.54) ALDH1A1
SCHEMBL8997657 0.86 HTT (0.54) ALDH1A1
SCHEMBL30960411 0.86 HTT (0.54) ALDH1A1
SCHEMBL686629 0.86 HTT (0.54) ALDH1A1
SCHEMBL3937310 0.86 HTT (0.54) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10731159-B2 Cationic lipid DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-08-04 US disclosed
US-20200080086-A1 CATIONIC LIPID DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-03-12 US disclosed
EP-3020701-B1 NOVEL LIPID DAIICHI SANKYO CO LTD (JP) 2018-09-26 EP disclosed
US-20180051285-A1 CATIONIC LIPID DAIICHI SANKYO COMPANY, LIMITED (JP) 2018-02-22 US disclosed
US-9803199-B2 Cationic lipid DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-10-31 US disclosed
US-20160257951-A1 NOVEL LIPID DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-09-08 US disclosed
EP-3020701-A1 NOVEL LIPID DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-05-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160257951-A1 NOVEL LIPID NPC1L1, CETP, LIPC ALDH1A1 1863/4885CNR1 2859/4885CNR2 3109/4885
US-20180051285-A1 CATIONIC LIPID CETP, NPC1L1, LIPA ALDH1A1 2540/4885CNR1 3207/4885CNR2 3384/4885
US-20200080086-A1 CATIONIC LIPID CETP, NPC1L1, LIPA ALDH1A1 2540/4885CNR1 3207/4885CNR2 3384/4885
US-10731159-B2 Cationic lipid CETP, NPC1L1, LIPA ALDH1A1 2540/4885CNR1 3207/4885CNR2 3384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.